Table 3 Prevalence and odds ratio (OR) associated with adherence for each of the methods used

From: Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain

 

Physician report

Telephone questionnaire

Pharmacy administrative database

 

n (%)

ORa

n (%)

ORb

n (%)

ORc

Age at diagnosis

 ⩽49

183 (90.7)

1

138 (84.8)

1

176 (64.8)

1

 50–74

419 (95.5)

1.71 (0.72–4.06)

330 (94.2)

2.75 (1.41–5.36)a

409 (79.0)

1.67 (1.03–2.70)a

 ⩾75

90 (94.4)

2.56 (0.68–9.63)

38 (86.8)

1.07 (0.37–3.12)

88 (67.0)

1.60 (0.76–3.36)

 P-value

0.075

 

0.003a

 

0.001a

 

Stage

 I

321 (93.5)

1

249 (92.8)

1

314 (74.2)

1

 IIA

200 (95.0)

0.89 (0.36–2.19)

142 (90.1)

0.81 (0.38–1.71)

192 (78.1)

1.09 (0.67–1.77)

 IIB

93 (93.5)

0.72 (0.25–2.1)

64 (87.5)

0.63 (0.25–1.56)

91 (64.8)

0.57 (0.32–1)a

 IIIA

42 (95.2)

1.2 (0.24–5.96)

30 (90.0)

0.62 (0.16–2.33)

40 (77.5)

1.09 (0.46–2.58)

 TNMx

36 (94.4)

1.01 (0.2–5.09)

21 (90.5)

0.87 (0.17–4.50)

36 (63.9)

0.67 (0.29–1.58)

 P-value

0.953

 

0.718

 

0.101

 

Surgical treatment

 Yes

681 (94.1)

1

505 (91.1)

1

663 (74.2)

1

 No

11 (90.9)

1.63 (0.16–17.14)

1 (100.0)

—

10 (40.0)

2.14 (0.51–8.98)

 P-value

0.654

 

0.911

 

0.015a

 

Type of surgical treatment

 Conservative breast surgery

536 (93.7)

1

394 (91.4)

1

523 (74.8)

1

 Radical breast surgery

145 (95.9)

1.34 (0.51–3.5)

111 (90.1)

1.09 (0.50–2.34)

140 (72.1)

1.47 (0.80–2.68)

 P-value

0.426

 

0.706

 

0.516

 

Radiotherapy

 No

132 (91.7)

1

85 (91.8)

1

128 (62.5)

1

 Yes

560 (94.6)

1.8 (0.8–4.05)

421 (91.0)

0.65 (0.27–1.57)

545 (76.3)

1.48 (0.93–2.36)

 P-value

0.193

 

0.815

 

0.001a

 

Neoadjuvant chemotherapy

 No

598 (94.1)

1

445 (90.8)

1

582 (74.6)

1

 Yes

94 (93.6)

0.79 (0.28–2.2)

61 (93.4)

1.79 (0.59–5.44)

91 (68.1)

0.57 (0.33–1)

 P-value

0.840

 

0.494

 

0.195

 

Adjuvant chemotherapy

 No

331 (92.1)

1

231 (91.8)

1

322 (68.6)

1

 Yes

361 (95.8)

2.14 (1.01–4.53)a

275 (90.5)

0.89 (0.44–1.81)

351 (78.3)

1.60 (1.05–2.43)a

 P-value

0.039a

 

0.628

 

0.004a

 

Endocrine therapy

 Tamoxifen

200 (89.0)

1

136 (89.7)

1

193 (60.6)

1

 Inhibitors

206 (94.7)

2.06 (0.82–5.17)

142 (90.9)

0.53 (0.19–1.48)

201 (78.1)

2 (1.18–3.38)a

 Tamoxifen + inhibitors

243 (98.4)

6.28 (1.93–20.45)a

197 (92.9)

0.65 (0.26–1.64)

238 (84.5)

2.27 (1.34–3.84)a

 Others

43 (94.1)

1.24 (0.38–4.03)

31 (87.1)

0.52 (0.15–1.84)

41 (51.2)

0.55 (0.27–1.13)

 P-value

<0.001a

 

0.630

 

<0.001a

 

Side effects b

 No

309 (92.2)

1

209 (90.9)

1

298 (69.5)

1

 Yes

383 (95.6)

1.81 (0.81–4.02)

297 (91.2)

1.06 (0.49–2.28)

375 (77.1)

1.25 (0.81–1.93)

 P-value

0.048a

 

0.508

 

0.016a

 
  1. Abbreviations: ORa=adjusted for centre, age at diagnosis, adjuvant chemotherapy, adverse effects and endocrine therapy; ORb=adjusted for centre, age at diagnosis; ORc=adjusted for centre, age at diagnosis, adjuvant chemotherapy, radiotherapy, side effects and endocrine therapy.
  2. n (%)=number of cases (% adherence); P-value: χ2-test.
  3. aStatistical significance, P<0.05.
  4. Adverse effects of physician report.
Back to article page